Journal of Drug Metabolism & Toxicology
Open Access

Federica Chiara

Biography

Chiara Federica Date and place of birth: 16/05/1966, Turin Nationality: Italian Address: Via Nani 57, Padova ITALY Education: Scientific High School in 1985 at the high school "M. Curie" Torino 1989 High top piano achieved at the Conservatory of Turin in 1994 Degree: Natural Sciences degree from the Faculty MM FF NN of Turin on 18/11/1994 with the 110/110 and mention 1996-2000 Ph.D. in Cellular Science and Technology, February 2000 Scientific Experience: 1990-1994 student at the Department of Animal Biology of the faculty FF MM NN Turin 1995-2000: Ph.D at the Institute for Research and Treatment of Cancer (IRCC) Division Molecular Oncology, Faculty of Medicine, headed by Prof. Paul M. Comoglio 2001-2002: Winner of Fellows Post-doc in "Medical Sciences, Experimental and clinical" issued by the University on 06/03/2001 2002-2003: Exchange post-doc at the 'Institute for Cancer Research Ludwig of Uppsala, Sweden, directed by Prof. Carl-Henrik Heldin 2003-2005: Junior group leader position in the laboratory of neurology at the Hospital of St. Aloysius Gonzaga Orbassano, Turin directed by Prof. Carlos Dotti 2006: winner in the selection process for qualifications and interview for the awarding of a grant for cooperation in research activities titled ".Molecular Dissection of the Permeability Transition Pore" at the Department of Experimental Biomedical Sciences of ' University of Padua, directed by prof. Paolo Bernardi. 2007: winner in the selection for the competition titles and research position at the Faculty of Medicine and Surgery of Padua Languages: English and French Research experience: 1) At the Institute of Cancer Research and Treatment (IRCC) Candiolo (Turin) headed by Prof. Paul Comoglio has been contributed to the project entitled: inhibition of the proto-oncogene Met antibodies using recombinant single chain. The strategy of the work involved the 'expression in mammalian cells a construct expressing engineered single-chain antibodies. The purpose was to block with the antibody produced by the cell itself kinase activity of the receptor MET hyperactive in tumors. These antibodies have been engineered by monoclonal antibodies directed against critical domains of the enzyme, or regulatory domains its kinase activity, and in the cell transfected with expression vectors Lentiviral. The project required knowledge of molecular biology and cell biology. 2) Analysis of the molecular determinants responsible for neoplastic transformation in the MET receptor. The enzyme tyrosine kinase MET has been observed to be constitutively activated in many cancers. This activity is deregulated underlying etiology of these cancers. In the group of Prof. Comoglio, for the first time it has been evidenced a regulatory mechanism of self-inhibition intrasterica that at the physiological level is only released following the activation mediated by the ligand binding. The insertion in the active site of point mutations identified in samples of patients suffering from renal papillary carcinoma and gastric carcinoma has shown that the removal allosteric inhibition induces activation of the receptor even in the absence of ligand. The project required the learning of molecular biology techniques for formaz

Research Interest

 Pharmaceutical Chemistry.Pharmaceutical Technology,Pharmaceutics

Relevant Topics